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Abstract  SA Fam Pract 2010;52(4):350-355
Background: Adherence to antiretroviral therapy (ART) is a strong predictor of progression to AIDS and death. It remains 
the most important potentially alterable factor that determines treatment outcomes. 
Methods: The study is a cross-sectional survey of self-reported adherence to ART and associated factors. It included a 
randomly selected sample of 100 adult patients who began ART between June 2006 and December 2007. A modified Adult 
AIDS Clinical Trials Group questionnaire was used. The analysis compared self-reported adherence levels by factor and 
viral load test results.
Results: Only 71% of patients had an adherence > 95%. Poor adherence was related to changes in daily routines (being 
away from home [21%] and busy with other things [17%]). All patients with symptoms suggestive of clinical depression 
had virologic failure. More unemployed patients (50.7%) had virologic failure than did employed patients (40%) (p = < 0.05). 
The clinic had a tenfold increase in patient enrolment and a ninefold decline in staff-to-patient ratio, and the proportion of 
patients lost to follow-up doubled in the preceding four years.
Conclusion: Adherence to ART was poor. The capacity of the clinic to manage patients adequately has declined significantly. 
Decentralisation of ART services to primary health care facilities should be considered. 
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Introduction
The backbone of the strategy to control the HIV/AIDS 
epidemic remains the prevention of HIV transmission. In 
generalised epidemics, the use of antiretroviral therapy 
(ART) is an additional component of HIV transmission 
prevention measures, as it reduces genital and plasma 
HIV-1 RNA.1-3 This prevention benefit is lost when ART is 
interrupted, either through a structured process or through 
non-adherence.4,5
As an increasing number of people in developing countries 
are put on lifelong ART, adherence to therapy has become 
a major concern. Adherence to treatment is an unresolved, 
complex phenomenon in the management of chronic 
conditions such as hypertension.6-8 Multiple doses and the 
side effects of medications are commonly cited factors 
associated with poor adherence.9 With the advent of 
antiretrovirals (ARVs), it has become clear that HIV/AIDS 
is a chronic condition for which adherence to therapy is of 
public health relevance.10,11 
Adherence to ART is the second strongest predictor 
of progression to AIDS and death after CD4 count and 
remains the most important potentially alterable factor 
that determines treatment outcomes for patients with HIV/
AIDS.12-16 Unlike treatment for most chronic conditions, ART 
requires very high levels of adherence for an indefinite period 
to achieve the desired results.17 Near-perfect adherence 
levels of > 95% are required to optimise the outcomes 
of highly active antiretroviral therapy (HAART), such as 
minimised drug resistance, slowed disease progression, 
decreased hospitalisation and delayed death.18-21 
At the beginning of the national ART programme 
implementation in South Africa, patients were screened to 
establish their ability to adhere to therapy prior to enrolment. 
Later, pressures to scale up the ART programme made this 
screening less stringent. The need for ART remains high 
in South Africa, a middle-income country with the second 
highest number of people living with HIV/AIDS (PLWHA) 
in the world (5.7 million by the middle of 2008).22 By 2006, 
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764 000 PLWHA needed ART, of which less than half 
(353 945) were enrolled in the government ART programme 
and even fewer (273 400) received ARV.23 As in many 
other sub-Saharan African countries, the South African 
ART programmes have improved. Of the 889 000 people 
in need of ART in 2007, 488 739 (55%) were enrolled and 
371 731 (42%) were started on treatment.22 The successes 
of the scale-up of ART programmes in South Africa make 
it imperative that the health system now invests in patient 
retention in treatment and care programmes. 
The prevailing adherence levels in sub-Saharan Africa are 
far below the recommended 95%, with pooled estimates 
of 77%.24 Adherence to ART entails more than simply 
remembering to take medication. There is an underlying 
amalgam of social, cultural, economic and personal 
factors.25 In the South African context, the capacity of 
the weak public health system is an additional factor that 
adversely affects adherence.26 Although reported barriers 
to adherence are consistent across multiple settings 
and countries, studies have also shown that adherence 
levels and the profile of factors that influence it differ by 
settings.27-29 This study therefore proposes to assess the 
level of and validate (using viral load [VL] results) self-
reported adherence among patients attending the HIV clinic 
of the Rustenburg Provincial Hospital (RPH), South Africa. 
It also describes the determining factors associated with 




RPH serves a predominantly black population. Rustenburg 
is one of the fastest-growing cities in South Africa, home to 
large platinum mines with high unemployment rates. RPH 
serves as a referral hospital for three district hospitals, three 
community health centres and seven primary health clinics. 
Its wellness clinic provides ART services free of charge. 
When there are no complications, patients attend the clinic 
on a monthly basis for ARV refill and every six months for 
laboratory test monitoring.
Study population and sample
RPH had 6 500 registered patients on its ART programme 
by the middle of 2008. To be included in the study, a patient 
had to be adult (18 years and above), be ARV naïve, be 
self-administering medication at home and have started 
treatment between 1 June 2006 and 31 December 2007. 
The patient had to have been on treatment for a period 
of between 12 and 18 months. The clinic register served 
as the sampling frame. A sample size of 100 patients was 
established. A target of 10 randomly selected patients 
was set per day. Each morning, all the patients in the 
appointment diary who complied with the inclusion criteria 
were allocated a number. Coupons bearing these numbers 
were put in a hat and randomly drawn to make the selection 
of the 10 to participate in the study. These patients were 
approached for consent as they arrived at the clinic. 
Those who refused were replaced by another draw. Ethical 
approval was obtained from the Faculty of Health Sciences, 
University of Pretoria.
Data sources, collection and management
The study used three sources of data: i) interview records 
of self-reported adherence levels, ii) the clients’ clinical/
hospital files for the VL test results and iii) the monthly/yearly 
statistics report of the clinic. Data were collected over three 
weeks during normal clinic hours. Prior to the interview, 
informed consent was sought. The patients were provided 
with an information sheet before consultation and afforded 
the opportunity to ask questions. It was made clear to them 
that refusal to participate would not jeopardise their access 
to services at the hospital. The interviews lasted about 
20 minutes. After normal consultation, patients who 
consented to participate were taken to a designated private 
room within the clinic where the interviews were conducted. 
The patient brought along his or her hospital file. The 
principal researcher interviewed participants in English, 
using the self-report adherence questionnaire. When 
needed, a trained assistant fluent in the local language 
(Setswana) acted as an interpreter. The questionnaire was 
an abridged version of that developed by the Adult AIDS 
Clinical Trials Group.30 Seven days was the time frame used 
to establish whether or not a patient had missed a dose 
as recall over a short time frame is more valid than over a 
longer time frame.31 
The questionnaire had closed-ended questions grouped 
in three sections: the first for general demographics, the 
second for self-reported adherence (including the patient’s 
latest VL) and the third for factors influencing adherence. 
The percentage adherence was calculated as the number of 
times the patient recalled to have taken medication (morning 
and evening doses) in the preceding week divided by the 
total number of doses prescribed for the week, multiplied 
by 100.
The VL test results were recorded from the patient’s file 
immediately after the interview. The most recent VL results 
as recorded in the patient’s file at the day of interview were 
recorded on the questionnaire. Clinicians are required to 
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staple laboratory test results on the patient files as well as 
transcribe the results in the clinical notes. The frequency 
and timing of VL measurement are determined by national 
guidelines32 as well as the discretion of the clinician. Patients 
on ART undergo an initial baseline VL assessment followed 
by another VL test within 4–6 months of initiating treatment 
to ascertain good virologic response. Thereafter, VL testing 
is done six-monthly to ensure that virologic success is 
maintained. All VL testing is conducted by the hospital 
laboratory, which is part of the National Health Laboratory 
Service of South Africa.
Operational definitions and outcome measures
• Adherence: With respect to HIV/AIDS care specifically, 
medication adherence has been defined as the ability 
of the PLWHA to be involved in choosing, starting, 
managing and maintaining a given therapeutic 
combination medication regimen to control viral (HIV) 
replication and improve immune function.20
• Optimal adherence: This is the level of adherence 
needed to maximally suppress viral replication in 
patients receiving HAART, estimated to be at least 
95%.15
• Virologic failure: This is defined in the South African 
national guidelines as failure to achieve a VL < 400 
copies/mL within 4–6 months of starting therapy.31
• Capacity assessment: The study used as norm the 
South African guidelines recommendation of an average 
of 12.5 staff to care for 500 patients on ART.31
Data analysis and statistics
To validate the self-reported adherence levels elicited from 
the interviews, self-reports were compared to VL test result 
interpretation (virologic failure). Data were captured on 
Microsoft Excel and imported on STATA 8.0 for analysis. 
Frequency, percentage, cross-tables and histograms were 
used to summarise the data. The ARV adherence levels 
were expressed as a percentage. The Fischer exact test 
was used to compare the levels of agreement between the 
means of self-reported adherence level and virologic failure. 
The p value (< 0.05) from the Fischer and Chi-squared tests 
was used to assess whether differences were significant. 
Results
A response rate of 95.3% was achieved. Consent was 
sought from 105 patients at the wellness clinic during the 
study period; five patients declined to participate in the 
study. There were more female (73) than male respondents 
(27). There was no difference in the proportion of men and 
women with virologic failure (see Table I). 
The majority (65%) of respondents were unemployed. 
Virologic failure was recorded in significantly higher 
proportions among unemployed patients (50.7%) compared 
to employed patients (40%) (p < 0.05) (see Table II). Slightly 
more than a third of patients (34%) reported psychological 
factors (feeling sad, unhappy or stressed) among the 
reasons affecting adherence. These factors correlated well 
with virologic failure. All patients (100%) feeling unhappy or 
sad and 85.7% of patients feeling stressed had virologic 
failure (p < 0.01).
Being away from home and being busy were the most 
commonly reported contextual factors affecting adherence. 
Virologic failure among patients who reported these factors 
was high. Seventy-one per cent of patients who were 
away and 88% of those who were busy with other things 
had virologic failure. Regimen factors were also important. 
Virologic failure among patients who reported being “asleep 
when medication was due” and “avoiding side effects” was 
81% and 100% respectively. 
Virologic failure was present in slightly less than half of the 
respondents (47%). Virologic failure was higher among 
patients who reported low adherence levels (see Table III). 
There was alignment between self-reported adherence 
levels and virologic failure. Three-quarters (77.7%) of 
patients who reported < 90% adherence had virologic 
failure. Failure was much less (only 33.8%) among patients 
who reported > 95% adherence (p < 0.01).
The clinic has experienced considerable growth in the 
number of HIV-positive patients registered, from 1 373 
patients in 2004 to 9 182 by 2007. By the end of 2004, 
Table I: Gender distribution and virologic failure among study participants
n













Table II: Determinants of adherence and virologic failure among study 
participants
Determinants of adherence n
Virologic failure n (%)
p value
Yes No
Unemployed                                     65 33 (50.7) 32 (49.3) 0.86
Employed 35 14 (40.0) 21 (60.0) 0.09
Feeling unhappy or sad 13 13 (100.0) 0 (0.0) 0.001
Feeling stressed 21 18 (85.7) 3 (14.3) 0.001
Never forgot 37 0 (0.0) 37 (100.0) 0.001
Away from home 21 15 (71.4) 6 (28.6) 0.006
Busy with other things 17 15 (88.2) 2 (11.8) 0.001
Asleep when medication was due 22 18 (81.8) 4 (18.2) 0.001
Avoiding side effects 8 8 (100.0) 0 (0.0) 0.001
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571 HIV-positive patients were receiving ARV. This number 
increased to 5 800 patients receiving ARV in 2007 (see 
Figure 1). 
The number of patients on ARV who were recorded as lost to 
follow-up (including known deaths, dropouts and transfers) 
was 117 in 2004, increasing steadily to 1 293, 1 988 and 
2 436 in 2005, 2006 and 2007 respectively. In relative terms, 
the loss to follow-up had doubled in three years, from 21% 
in 2004 (117/571), reaching 42% in 2007 (2 436/5 800). 
The increase in the number of staff, however, has not been 
proportional. Except for the year 2006 when the wellness 
clinic had 32 staff, the staffing level was kept relatively 
unchanged at 25 in 2004 and 26 in 2005 and 2007. When 
related to the number of patients currently receiving ARV 
at the wellness clinic, only in 2004 was the actual staff-to-
patient ratio in compliance with the recommended norm of 
12.5:500 of the national ART programme. There had been 
a steady decline in staff-to-patient ratio between 2004 and 
2007 (see Figure 2).
Discussion
This study reveals that 82% of respondents reported to have 
achieved at least 90% adherence to their ARV regimen in 
the week preceding the survey. This is, however, not optimal 
as a greater than 95% adherence level is required to sustain 
viral suppression and avoid resistance. Although 71% of 
respondents in this study reported > 95% adherence levels, 
this is lower than findings from similar local and African 
settings.32-34 Not surprisingly, the proportion of patients with 
virologic failure was significantly higher among those with 
adherence levels less than 95%.
Overall, virologic failure was present in almost half (47%) 
the respondents, a much higher proportion than the 
average rate in South Africa, which ranges between 10% 
and 16%.26 The poor results suggested by this study may 
be partly explained by the fact that the clinic has exceeded 
its optimal capacity for quality service delivery. Evidence 
suggests that good counselling at an HIV clinic is important 
in improving adherence.35 This, however, requires more time 
for provider-client interaction,36 which is not always possible 
in clinics with a high workload and staff shortage. 
Staff shortage is a common problem faced by ART 
programmes that scale up rapidly, such as seen in 
Malawi, Uganda and Botswana where increase in staffing 
lagged behind the rates of enrolment of patients in the 
ART programmes.21,37 Decentralisation of services and 
task shifting as practised in Lusikisiki and the Free State 
should be considered and rolled out nationally to alleviate 
the problems of capacity at major ART clinics.38–40 There is 
now considerable evidence across Africa of the feasibility of 
integrated district-based approaches that achieve universal 
access while maintaining quality and outcomes.26,37,41,42 
Providing ART at the primary health care clinic level 
increases the number of entry points to care, while the 
greater proximity of services encourages retention in care.38 
However, a rapid transfer of large numbers of patients 
can overwhelm minimally staffed clinics if appropriate 
steps are not taken. In addition to the additional workload, 
Table III: Self-reported adherence and virologic failure among study 
participants
Adherence levels
> 95% 90–95% < 90%
Fisher’s 
exact
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Figure 1: Trends in patient enrolment at RPH’s wellness clinic
2004 2005 2006 2007
  HIV+ patients 
registered 1,373 4,630 7,189 9,182
  No. HIV+ started 
on ARV 571 2,678 4,416 5,800
  No. HIV+ currently 

















% loss to follow-up
No. staff per 500 patients currently on ARV
Figure 2: Trends in loss to follow-up and staffing norms at RPH’s  
wellness clinic
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clinic staff may not feel confident enough to carry out their 
new responsibility, particularly if training and supervision 
mechanisms are not adequately provided.
In assessing the determinant of adherence, the limitations 
of this study are inherent to the use of a self-report 
questionnaire, namely social desirability bias and recall 
bias. To minimise the effect of these limitations, patients 
were assured of and provided with confidentiality of 
their answers on adherence. A seven-day recall time, an 
accepted time frame to minimise recall bias in research on 
ARV adherence, was used. 
There is some evidence in South Africa that low 
socioeconomic status (an index composed of education, 
welfare, unemployment and overcrowding status with 
annual income) is not a barrier to successful ARV therapy. 
43 Our study, however, suggests that unemployment was an 
important factor in adherence among study participants. The 
prevalence of virologic failure among unemployed patients 
was higher than among their employed counterparts. 
The most common general factors were changes in daily 
routines, being away from home and being occupied at the 
time of having to take the ARV dose. The avoidance of side 
effects was a common regimen factor affecting adherence 
in our study, similar to findings elsewhere.25 This reinforces 
the call for using combination ARVs and ARVs with fewer 
dosing frequencies and side effects. 
The findings of our study suggest that a poor psychological 
state was associated with poor adherence. Other studies 
have also shown significant association between poor 
psychological states and non-adherence.25,44,45 Randomised 
controlled trials in Europe and the United States have 
confirmed that dedicating time to individualised counselling 
and education increases patients’ sense of self-worth and 
efficacy.46-48 Although this may not be feasible in Africa 
given the current capacity challenges, patients should 
nevertheless be systematically screened for depressive 
diseases and treated accordingly.
In conclusion, the performance of the wellness clinic, 
in relation to adherence to ARV, was relatively poor. 
Unemployment, a complex non-health sector problem, was 
an important factor but cannot be resolved at clinic level. 
Drug-related factors can be remedied by the selection 
and procurement of ARVs with a better frequency-of-
administration and side-effect profile. The alleviation of staff 
shortage will improve the quality of counselling and doctor-
patient interaction. If the recruitment of additional staff is 
not possible, the capacity of large ART clinics, such as our 
study site, should be protected by decentralisation of ART 
services to smaller centres (primary health care centres and 
clinics).
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